Catalog No.
VHJ28801
Species reactivity
Human
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Leucine-rich repeat-containing protein 15, Leucine-rich repeat protein induced by beta-amyloid homolog, hLib, LRRC15, LIB
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8TF66
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0219
Impact of site-specific conjugation strategies on the pharmacokinetics of antibody conjugated radiotherapeutics., PMID:39378827
Impact of site-specific conjugation strategies on the pharmacokinetics of antibody conjugated radiotherapeutics., PMID:39378827
CAFs-Associated Genes (CAFGs) in Pancreatic Ductal Adenocarcinoma (PDAC) and Novel Therapeutic Strategy., PMID:38892190
CAFs-Associated Genes (CAFGs) in Pancreatic Ductal Adenocarcinoma (PDAC) and Novel Therapeutic Strategy., PMID:38892190
Leucine-Rich Repeat Containing 15-Mediated Cell Adhesion Is Essential for Integrin Signaling in TGF-β1-Induced PDL Fibroblastic Differentiation., PMID:38051601
Leucine-Rich Repeat Containing 15-Mediated Cell Adhesion Is Essential for Integrin Signaling in TGF-β1-Induced PDL Fibroblastic Differentiation., PMID:38051601
Development of Anti-LRRC15 Small Fragments for Imaging Purposes Using a Phage-Display ScFv Approach., PMID:36293532
Development of Anti-LRRC15 Small Fragments for Imaging Purposes Using a Phage-Display ScFv Approach., PMID:36293532
Exploiting LRRC15 as a Novel Therapeutic Target in Cancer., PMID:35260879
Exploiting LRRC15 as a Novel Therapeutic Target in Cancer., PMID:35260879
Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications., PMID:34656365
Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications., PMID:34656365
Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer., PMID:34654724
Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer., PMID:34654724
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors., PMID:33820780
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors., PMID:33820780
ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium., PMID:33298592
ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium., PMID:33298592
LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies., PMID:33063919
LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies., PMID:33063919
LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications., PMID:32210091
LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications., PMID:32210091
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates., PMID:29764866
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates., PMID:29764866
Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens., PMID:24641868
Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens., PMID:24641868
For research use only. Not for human or drug use.
